Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
AnGes said on September 18 that the US FDA has awarded Breakthrough Therapy designation to its HGF gene therapy Collategene (beperminogene perplasmid) for the treatment of peripheral arterial disease.Peripheral arterial disease, which affects around 200 million people worldwide, can lead…
To read the full story
Related Article
- AnGes Taps Boehringer for Collategene Manufacturing
August 21, 2025
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





